NCT00976404 - Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

July 31, 2013

Study Completion Date

June 30, 2014

Conditions

HIV Infection

Interventions

BIOLOGICAL

DNA + HIV-rAd5 vaccine

4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)

DRUG

ART intensification (raltegravir)

raltegravir 400 mg PO BID for 56 weeks

DRUG

ART intensification (maraviroc)

maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks

Trial Locations (3)

Cornell University, New York

Northwestern University, Chicago

University of California San Francisco, San Francisco